PERsistent Sitagliptin treatment & Outcomes (PERS&O 2.0) study, long-term results: a real-world observation on DPP4-inhibitor effectiveness.

Antonio Carlo BossiValentina De MoriCarlotta GaleoneDavide Pietro BertolaMargherita GaitiAnnalisa BaliniDenise BerziFranco ForloniGiancarla MeregalliFederica Turati

Published in: BMJ open diabetes research & care (2021)

Patients with T2D treated with sitagliptin achieved an improvement in metabolic control and a reduction in CV risk and did not experience relevant adverse events.

Keyphrases

randomized controlled trial
systematic review
newly diagnosed